Research in the Patrick Breysse Lab seeks to better understand the biological, chemical and physical factors that can impact a patient’s health. Our team is currently studying the effects of indoor and outdoor air pollution on childhood asthma, respiratory tract infections, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. We also conduct research on secondhand smoke exposure around the world and have participated in a range of health and exposure studies in Peru, Nepal, Mongolia, Columbia and India.

The Arturo Casadevall Lab uses a multidisciplinary approach to explore two key topics within microbiology and immunology: how microbes cause disease and how hosts can protect themselves against those microbes. Much of our research focuses on the fungus Cryptococcus neoformans, which frequently causes lung infections in people with impaired immunity. We also work with the microorganism Bacillus anthracis, a bacterium that causes anthrax and is frequently used in biological warfare. Our goal is to devise antibody-based countermeasures to protect against this and other similar threats.

Research in the Andrea Cox Lab explores the immune response in chronic viral infections, with a focus on HIV and the hepatitis C virus (HCV). In our studies, we examine the role of the immune response upon exposure to HCV by examining responses to HCV in a longitudinal, prospective group of high-risk individuals. This enables us to compare the innate, humoral and cellular immune responses to infection with clearance versus persistence. Through our findings, we seek to identify mechanisms of protective immunity against HCV infection and improve HCV vaccine design.

Research in the Asad Latif Lab focuses on patient safety and quality improvement. Our key interests include preventing hospital-acquired infections and improving health systems, the evaluation and prevention of healthcare errors and the utility of telemedicine in intensive care units. One recent study focused on reducing medication errors (the single most common type of error in healthcare) related to drug formulation in the intensive care unit.

We study human B cells and neutralizing antibody responses against hepatitis C virus (HCV), hepatitis B virus (HBV), SARS-CoV-2, and respiratory syncytial virus (RSV). Our overarching hypothesis is that understanding the B cell response in individuals who naturally control infections, and those who have been vaccinated, can help us to understand the basic biology behind successful immune responses, leading to design of more effective vaccines. A particular technical strength of our laboratory is high dimensional flow cytometric analysis of antigen-specific B cells, which allows us to phenotype these rare cells, and also to sequence B cell receptor (BCR) repertoires and isolate virus-neutralizing monoclonal antibodies (mAbs).